[go: up one dir, main page]

WO2006010070A3 - Compositions and methods related to peptides that selectively bind leukemia cells - Google Patents

Compositions and methods related to peptides that selectively bind leukemia cells Download PDF

Info

Publication number
WO2006010070A3
WO2006010070A3 PCT/US2005/024414 US2005024414W WO2006010070A3 WO 2006010070 A3 WO2006010070 A3 WO 2006010070A3 US 2005024414 W US2005024414 W US 2005024414W WO 2006010070 A3 WO2006010070 A3 WO 2006010070A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia cells
targeting peptides
compositions
peptides
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/024414
Other languages
French (fr)
Other versions
WO2006010070A2 (en
Inventor
Diana Jaalouk
Wadih Arap
Renata Pasqualini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2006010070A2 publication Critical patent/WO2006010070A2/en
Publication of WO2006010070A3 publication Critical patent/WO2006010070A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention provides additional methods and compositions for the preparation and use of targeting peptides that are selective and/or specific for leukemia. In some embodiments, the invention concerns particular targeting peptides selective or specific for leukemia cells, including but not limited to SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7. Other embodiments concern such targeting peptides attached to therapeutic agents. In other embodiments, leukemia or other targeting peptides may be used to selectively or specifically deliver therapeutic agents to target cells, such as leukemia cells. In certain embodiments, the subject methods concern the identification, preparation, and use of targeting peptides selective or specific for a given target cell, tissue or organ, such as leukemia cells.
PCT/US2005/024414 2004-07-10 2005-07-11 Compositions and methods related to peptides that selectively bind leukemia cells Ceased WO2006010070A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58681404P 2004-07-10 2004-07-10
US60/586,814 2004-07-10

Publications (2)

Publication Number Publication Date
WO2006010070A2 WO2006010070A2 (en) 2006-01-26
WO2006010070A3 true WO2006010070A3 (en) 2006-05-26

Family

ID=35785773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024414 Ceased WO2006010070A2 (en) 2004-07-10 2005-07-11 Compositions and methods related to peptides that selectively bind leukemia cells

Country Status (1)

Country Link
WO (1) WO2006010070A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2338898A1 (en) * 2006-03-09 2011-06-29 The Board of Regents of the University of Texas System Compositions and methods related to profiling a plurality of cell lines based on peptide binding
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
JP2010520238A (en) 2007-03-01 2010-06-10 マリンクロット インコーポレイテッド Integrated photoactive small molecule and integrated photoactive small molecule use
WO2009018405A1 (en) 2007-07-31 2009-02-05 Mallinckrodt Inc. Integrated photoactive agents and uses thereof
KR100968839B1 (en) * 2008-02-25 2010-07-09 경북대학교 산학협력단 Polypeptides that specifically bind to phosphatidylserine and uses thereof
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
WO2011031955A2 (en) * 2009-09-11 2011-03-17 Mallinckrodt Inc. Optical monitoring of leukemia
WO2011084571A2 (en) 2009-12-16 2011-07-14 Mallinckrodt Inc. Azide derivatives for phototherapy
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
WO2013038392A1 (en) * 2011-09-18 2013-03-21 Ariel-University Research And Development Company, Ltd. Peptides useful for binding to b-cell leukemic cells, conjugates, and compositions comprising same and uses thereof
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018085413A1 (en) * 2016-11-01 2018-05-11 Northwestern University Layer-by-layer sorting of rhenium disulfide via high-density isopycnic density gradient ultracentrufugation
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US20030054375A1 (en) * 2000-01-31 2003-03-20 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
US20030054375A1 (en) * 2000-01-31 2003-03-20 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies

Also Published As

Publication number Publication date
WO2006010070A2 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
WO2006010070A3 (en) Compositions and methods related to peptides that selectively bind leukemia cells
EP2789628A3 (en) Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2006004910A3 (en) Improved bispecific antibodies
WO2009105671A3 (en) Methods and compositions related to peptides and proteins with c-terminal elements
EP2583976A3 (en) Peptide vaccines with SEQ ID NO: 210, 196, 202, 213, 214, 214 or 223 for cancers expressing tumor-associated antigens
WO2007067682A3 (en) In vivo cell surface engineering
WO2008079973A3 (en) Egfr binding peptides and uses thereof
WO2006133271A3 (en) Compositions and methods relating to target-specific photodynamic therapy
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
WO2008063291A3 (en) Polypeptide ligands for targeting cartilage and methods of use thereof
GB201001602D0 (en) Oligopeptidic compounds and uses therof
UA100127C2 (en) Peptide cdh3 and drug containing it
WO2006124892A3 (en) Modulators of alpha-synuclein toxicity
WO2008033987A3 (en) Compositions and methods to prevent cancer with cupredoxins
WO2007044396A3 (en) Fibronectin polypeptides and methods of use
WO2007035213A3 (en) Transgenic ungulates expressing ctla4-ig and uses thereof
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
WO2005030928A3 (en) PORCINE INVARIANT CHAIN PROTEIN, FULL LENGTH cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2006096774A3 (en) Composition and methods for delivering carbon monoxide (co) and nitric ozide (no) co to tissue using heme proteins as carriers
WO2006057003A3 (en) Induction of neurogenesis and stem cell therapy in combination with copolymer 1
WO2008040190A8 (en) Small peptides for anti-angiogenesis and use thereof
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
GB0524477D0 (en) Isolated T cell receptors which specifically bind to vygfvracl-hla-24
MXPA05010575A (en) Peptabody for cancer treatment.
WO2005090393A3 (en) Multimeric protein toxins to target cells having multiple identifying characteristics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase